Our history
While Ontada is a new business, the assets and the people that make up this organization have a long history of creating value for stakeholders across the field of oncology and driving better patient outcomes for those at the center of the fight against cancer.
1990s
2000
iKnowMed Generation 0 (formerly known as KnowChart) is introduced to the market. This software allowed providers to record and access patient data for clinical guidelines, protocols and clinical trials and would eventually become what is known today as iKnowMed Generation 2, our market-leading electronic health record (EHR) for oncology practices.
iKnowMed Generation 1, the next generation of our oncology EHR, is introduced to the market.
Ontada
SM
KnowChart, by KnowMed Systems
iKnowMed Generation 1
2008
McKesson acquires Onmark , a GPO focused on community-based oncology. McKesson successfully folded the National Oncology Alliance and Onmark into a single GPO under the Onmark banner. More than 2,700 member practices and 4,700 physicians were represented by the merger.
2010
McKesson acquires US Oncology, creating
a combined organization dedicated to delivering a comprehensive set of solutions to the oncology industry. US Oncology is later rebranded as The US Oncology Network.
Through the acquisition of The US Oncology Network, McKesson inherits iKnowMed EHR, enhancing our ability to improve the quality and efficiency of cancer treatment across all settings.
2006
McKesson acquires the National Oncology Alliance, Inc. (NOA), a best-in-class specialty group purchasing organization (GPO).
2007
McKesson acquires Oncology Therapeutics Network (OTN),
a distributor of specialty pharmaceuticals.
®
2016
McKesson purchases Vantage Oncology, LLC, a leading national provider of radiation oncology, medical oncology and integrated cancer care, and Biologics, Inc., an oncology pharmacy services company, creating a more expansive suite of offerings in the oncology space.
McKesson announces a comprehensive solution to support community-based oncology practices participating in The Center for Medicare and Medicaid Innovation’s (CMMI) Oncology Care Model (OCM).
2014
Clear Value Plus is introduced to the market. Clear Value Plus presents Value Pathways powered by NCCN and NCCN Guidelines within the clinical workflow, offering integrated financial information, real-time reporting and benchmarking, and the ability to interface with an EHR.
The first conversion of an iKnowMed Generation 1 customer to the iKnowMed Generation 2 platform occurs.
2013
iKnowMed Generation 2 is introduced to the market. The next generation of our electronic health record (EHR) was developed in collaboration with oncologists. Drawing upon their daily clinical experiences, more than 200 physicians came together to help create a system that advances the quality and efficiency of cancer care delivery.
2012
McKesson collaborates with the National Comprehensive Cancer Network (NCCN) to offer new Value Pathways for Cancer Care. This first-of-its-kind software allowed physicians to review treatment options and their relevant clinical attributes against Value Pathways powered by NCCN and NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) at the point of care.
™
®
®
SM
McKesson collaborates with the National Comprehensive Cancer Network (NCCN) to offer new Value Pathways for Cancer Care. This first-of-its-kind software allowed physicians to review treatment options and their relevant clinical attributes against Value Pathways powered by NCCN and NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) at the point of care.
™
®
®
2012
iKnowMed Generation 2 is introduced to the market. The next generation of our electronic health record (EHR) was developed in collaboration with oncologists. Drawing upon their daily clinical experiences, more than 200 physicians came together to help create a system that advances the quality and efficiency of cancer care delivery.
2013
Clear Value Plus is introduced to the market. Clear Value Plus presents Value Pathways powered by NCCN and NCCN Guidelines within the clinical workflow, offering integrated financial information, real-time reporting and benchmarking, and the ability to interface with an EHR.
The first conversion of an iKnowMed Generation 1 customer to the iKnowMed Generation 2 platform occurs.
SM
2014
2020
Biomarker Test Guidelines are added to iKnowMed EHR to support precision medicine. This capability suggests molecular tests by disease type along with vetted laboratory vendors to help physicians make informed decisions on the most personalized and effective ways to treat cancer for each patient.
2019
Aetion and McKesson launch a strategic collaboration focused on advancing the use of real-world evidence. The partnership will provide best-in-class solutions in multiple tumor types, including breast, lung and melanoma cancers.
McKesson announces that it is participating in Phase II of the Friends of Cancer Research (Friends) Real-World Evidence (RWE) pilot project to advance the understanding and inform future uses of RWE.
2018
Providers using iKnowMed EHR are eligible for incentive payments under Merit-Based Incentive Payments System (MIPS).
2017
McKesson expands its agreement with the NCCN, adding five additional disease states to Value Pathways.
A real-world evidence study conducted by McKesson plays a key role in FDA’s approval for a first-line indication for a rare disease. McKesson prepared and supplied analysis from a standard-of-care trial for a drug that treats metastatic Merkel Cell Carcinoma (mMCC), a form of skin cancer. This is the first time that real-world data, which in this case was pulled from McKesson’s iKnowMed EHR, is part of a regulatory approval in oncology.
Ontada is launched. Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer.
2016
McKesson purchases Vantage Oncology, LLC,
a leading national provider of radiation oncology, medical oncology and integrated cancer care, and Biologics, Inc., an oncology pharmacy services company, creating a more expansive suite of offerings in the oncology space.
McKesson announces a comprehensive solution to support community-based oncology practices participating in The Center for Medicare and Medicaid Innovation’s (CMMI) Oncology Care Model (OCM).
2017
McKesson expands its agreement with the NCCN, adding five additional disease states to Value Pathways.
A real-world evidence study conducted by McKesson plays a key role in FDA’s approval for a first-line indication for a rare disease. McKesson prepared and supplied analysis from a standard-of-care trial for a drug that treats metastatic Merkel Cell Carcinoma (mMCC),
a form of skin cancer. This is the first time that real-world data, which in this case was pulled from McKesson’s iKnowMed EHR, is part of
a regulatory approval in oncology.
2018
Providers using iKnowMed EHR are eligible for incentive payments under Merit-Based Incentive Payments System (MIPS).
McKesson launches Data, Evidence and Insights, a part of the new McKesson Life Sciences portfolio designed to support biopharma clinical and commercial strategy development.
2019
Aetion and McKesson launch a strategic collaboration focused on advancing the use of real-world evidence. The partnership will provide best-in-class solutions in multiple tumor types, including breast, lung and melanoma cancers.
McKesson announces that it is participating in Phase II of the Friends of Cancer Research (Friends) Real-World Evidence (RWE) pilot project to advance the understanding and inform future uses of RWE.
2020
Biomarker Test Guidelines are added to iKnowMed EHR to support precision medicine. This capability suggests molecular tests by disease type along with vetted laboratory vendors to help physicians make informed decisions on the most personalized and effective ways to treat cancer for each patient.
Ontada is launched. Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer.
